You are here

Similar Blood Glucose Improvements Seen With Linagliptin and Glimeperide

The publication describes a 2-year, randomized, double-blind study in 1,552 patients evaluating the efficacy of linagliptin compared with glimepiride, as measured by a reduction in HbA1c from baseline, in patients uncontrolled on metformin alone.

Although based on a small number of cardiovascular events (N = 38), the investigators were able to evaluate and compare the incidences of major cardiovascular events between linagliptin and glimepiride for the first time.

The profile of linagliptin versus glimepiride is being further investigated in the ongoing, head-to-head outcomes trial CAROLINA, the first outcomes study to compare a DPP-4 inhibitor with an active comparator. The study is evaluating 6,000 patients over a 5-year period. Patient recruitment is scheduled to be completed this year.

Tradjenta is marketed in Europe as Trajenta (linagliptin) tablets and in other global markets as a once-daily tablet that is used along with diet and exercise to improve glycemic control in adults with type-2 diabetes.

Read the news release from Boehringer Ingelheim.

More Headlines

Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
First and Only Treatment Reduces Depressive Symptoms Within Days
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time